AZN AstraZeneca PLC

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) said Monday that a phase 3 trial of a three-drug combination for the treatment of chronic obstructive pulmonary disease met eight out of its main objectives.

The Anglo-Swedish pharmaceutical company said that the results of the Kronos trial, which compared a combination of budesonide, glycopyrronium and formoterol with a number of rival therapies, was published in the journal The Lancet Respiratory Medicine.

The three-drug cocktail called PT010 showed a significant reduction of exacerbations in patients with the disease compared with rival therapy, the company said.

AstraZeneca said it plans on making a first regulatory submission for the drug in the second half of the year.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

September 17, 2018 02:49 ET (06:49 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.